34 results on '"Tadashi Shimada"'
Search Results
2. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
- Author
-
Tomohide Tamura, Naoyuki Nogami, Masao Harada, Haruyasu Murakami, Hiroshige Yoshioka, Yuichiro Ohe, Akira Inoue, Makoto Nishio, Kengo Takeuchi, Takashi Seto, Hiroshi Kuriki, Katsuyuki Kiura, Makoto Maemondo, Tadashi Shimada, Kazuhiko Nakagawa, Toyoaki Hida, and Tomohiro Tanaka
- Subjects
0301 basic medicine ,Oncology ,Alectinib ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Time Factors ,medicine.drug_class ,medicine.medical_treatment ,Carbazoles ,Antineoplastic Agents ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Piperidines ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Carcinoma ,Anaplastic lymphoma kinase ,Humans ,Anaplastic Lymphoma Kinase ,Lung cancer ,Thoracic Oncology ,Survival rate ,Aged ,Hyperbilirubinemia ,Chemotherapy ,business.industry ,Cancer ,Receptor Protein-Tyrosine Kinases ,ORIGINAL REPORTS ,Middle Aged ,medicine.disease ,Surgery ,ALK inhibitor ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,Retreatment ,Disease Progression ,Female ,Symptom Assessment ,business ,Follow-Up Studies - Abstract
Purpose Alectinib is an anaplastic lymphoma kinase (ALK) –specific kinase inhibitor that seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overall response rate. To assess progression-free survival (PFS) and overall survival (OS), patients from the phase II part of AF-001JP were followed up for approximately 3 years. Patients and Methods Oral alectinib 300 mg was administered twice per day to patients with ALK inhibitor–naïve, ALK-positive NSCLC who had progressed after one or more regimens of previous chemotherapy. In this long-term follow-up, efficacy (PFS, OS), correlation between tumor shrinkage and PFS, safety of alectinib, and relief of cancer symptoms were evaluated. Results At the updated data cutoff (September 10, 2015; first patient in August 30, 2011, last patient in April 18, 2012), 25 of 46 phase II patients were still receiving alectinib. Disease progression was confirmed in 18 patients (39%); median PFS was not reached (3-year PFS rate, 62%; 95% CI, 45 to 75). Fourteen patients had brain metastases at baseline; of these, 6 remained in the study without CNS and systemic progression. Tumor shrinkage and PFS showed no correlation. The 3-year OS rate was 78% (13 events). The most common treatment-related adverse event (all grades) was increased blood bilirubin (36.2%). Most cancer symptoms were relieved early, and medication for symptoms was dramatically decreased during alectinib therapy. Conclusion Alectinib was effective in this 3-year follow-up with a favorable safety profile over a long administration period in ALK-positive NSCLC without previous ALK inhibitor treatment.
- Published
- 2017
3. Characteristics of Axillary Odor in the Modern Japanese Female
- Author
-
Takeshi Hara, Tadashi Shimada, Akiko Sawada, Maki Sawada, Mayumi Shimizu, Kasumi Maeda, and Ayumi Kyuka
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,AXILLARY ODOR ,business ,Dermatology - Published
- 2017
4. Formulation Development to Enhance the Residual Performance of Antimicrobial Agents on the Skin
- Author
-
Tadashi Shimada, Takeshi Hisahara, Hiroshi Matsui, and Keiji Kasahara
- Subjects
World Wide Web ,Thesaurus (information retrieval) ,Operations research ,business.industry ,Medicine ,Residual ,business ,Antimicrobial - Published
- 2017
5. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
- Author
-
Miyako Satouchi, Kazuhiko Nakagawa, Toyoaki Hida, Takashi Seto, Yuichiro Ohe, Katsuyuki Hotta, Makoto Nishio, Masahiro Tatsuno, Takashi Asakawa, Tadashi Shimada, Tomohiro Tanaka, Toshiaki Takahashi, Tomohide Tamura, and Koji Takeda
- Subjects
0301 basic medicine ,Alectinib ,Male ,Cancer Research ,Lung Neoplasms ,Pyridines ,Pharmacology ,Gastroenterology ,0302 clinical medicine ,Piperidines ,Carcinoma, Non-Small-Cell Lung ,Anaplastic Lymphoma Kinase ,Treatment Failure ,non‐small‐cell lung cancer ,General Medicine ,Fasting ,Middle Aged ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Absolute neutrophil count ,Original Article ,Female ,medicine.symptom ,medicine.drug ,Adult ,medicine.medical_specialty ,Carbazoles ,Disease-Free Survival ,03 medical and health sciences ,Young Adult ,Pharmacokinetics ,Crizotinib ,Clinical Research ,Internal medicine ,White blood cell ,medicine ,Humans ,Lung cancer ,Adverse effect ,Aged ,bioequivalence ,business.industry ,Receptor Protein-Tyrosine Kinases ,Original Articles ,medicine.disease ,Dysgeusia ,030104 developmental biology ,Therapeutic Equivalency ,Japanese ,Pyrazoles ,business - Abstract
Summary We report pharmacokinetics, efficacy, and safety data for a new 150 mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-naive and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40 mg and 150 mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg versus 150 mg; food effect with 150 mg; and safety. Thirty-five patients were enrolled; median treatment duration was 13.1 months (range 1.1−15.0). Under fasting conditions, exposure of the two formulations was similar; mean AUClast ± standard deviation 3230 ± 914 h•ng/mL versus 3710 ± 1040 h•ng/mL, respectively, for 150 mg versus 20/40 mg capsules. Food effect with 150 mg alectinib was negligible. Treatment-related adverse events in >20% of patients were constipation (31.4%), dysgeusia (25.7%), and decreased white blood cell and neutrophil count (22.9% each). No treatment-related grade 4/5 events occurred. Median time to response was 1.2 months (95% CI 1.1−2.1). For the full analysis set (n = 35) and crizotinib-failure subpopulations (n = 23), overall response rate was 70.0% (95% CI 50.6−85.3) and 65.0% (95% CI 40.8−84.6), and median progression-free survival was 13.9 months (95% CI 11.1−not reached) and 12.9 months (95% CI 3.9−not reached), respectively. The 150 mg capsule had a similar exposure profile to 20/40 mg capsules. Alectinib demonstrated promising efficacy and was well tolerated. This article is protected by copyright. All rights reserved.
- Published
- 2016
6. Vemurafenib (ZELBORAF® tablet 240 mg): pharmacological properties and clinical development overview
- Author
-
Tomoyuki Aoki, Kyoko Yamaguchi, Takahiro Mizui, Atsuko Kajihara, and Tadashi Shimada
- Subjects
0301 basic medicine ,Pharmacology ,Oncology ,medicine.medical_specialty ,business.industry ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Vemurafenib ,business ,medicine.drug - Published
- 2016
7. Evaluation of the Comfortable Cooling Sensation for the Development of Body Care Products
- Author
-
Hiroshi Matsui, Fumitaka Fujita, Maki Sawada, Masayuki Takaishi, and Tadashi Shimada
- Subjects
medicine.medical_specialty ,Physical medicine and rehabilitation ,Sensation ,medicine ,Psychology - Published
- 2015
8. Effects of the Application of Facial Cleansing Wipes on Male Skin Conditions
- Author
-
Mayumi Shimizu, Masayuki Takaishi, Kaori Saito, Fumitaka Fujita, Ayumi Yamaguchi, Jun Usukura, and Tadashi Shimada
- Published
- 2014
9. Vemurafenib (ZELBORAF
- Author
-
Tadashi, Shimada, Kyoko, Yamaguchi, Tomoyuki, Aoki, Atsuko, Kajihara, and Takahiro, Mizui
- Subjects
Proto-Oncogene Proteins B-raf ,Clinical Trials as Topic ,Sulfonamides ,Indoles ,Vemurafenib ,Neoplasms ,Humans ,Antineoplastic Agents ,Tablets - Published
- 2016
10. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- Author
-
Tomohiro Tanaka, Akira Inoue, Kengo Takeuchi, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Katsuyuki Kiura, Yuichiro Ohe, Tadashi Shimada, Makoto Nishio, Toyoaki Hida, Hiroshige Yoshioka, Tomohide Tamura, Naoyuki Nogami, Masao Harada, Makoto Maemondo, and Takashi Seto
- Subjects
Adult ,Male ,Alectinib ,medicine.medical_specialty ,Lung Neoplasms ,Maximum Tolerated Dose ,medicine.drug_class ,Carbazoles ,Adenocarcinoma ,Gastroenterology ,Immunoenzyme Techniques ,Piperidines ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Anaplastic Lymphoma Kinase ,Adverse effect ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,Gene Rearrangement ,Intention-to-treat analysis ,Ceritinib ,Crizotinib ,business.industry ,Receptor Protein-Tyrosine Kinases ,Gene rearrangement ,Middle Aged ,Prognosis ,Surgery ,ALK inhibitor ,Oncology ,Carcinoma, Squamous Cell ,Absolute neutrophil count ,Carcinoma, Large Cell ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor. Methods In this multicentre, single-arm, open-label, phase 1–2 study of CH5424802, we recruited ALK inhibitor-naive patients with ALK -rearranged advanced NSCLC from 13 hospitals in Japan. In the phase 1 portion of the study, patients received CH5424802 orally twice daily by dose escalation. The primary endpoints of the phase 1 were dose limiting toxicity (DLT), maximum tolerated dose (MTD), and pharmacokinetic parameters. In the phase 2 portion of the study, patients received CH5424802 at the recommended dose identified in the phase 1 portion of the study orally twice a day. The primary endpoint of the phase 2 was the proportion of patients who had an objective response. Treatment was continued in 21-day cycles until disease progression, intolerable adverse events, or withdrawal of consent. The analysis was done by intent to treat. This study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-101264. Findings Patients were enrolled between Sept 10, 2010, and April 18, 2012. The data cutoff date was July 31, 2012. In the phase 1 portion, 24 patients were treated at doses of 20–300 mg twice daily. No DLTs or adverse events of grade 4 were noted up to the highest dose; thus 300 mg twice daily was the recommended phase 2 dose. In the phase 2 portion of the study, 46 patients were treated with the recommended dose, of whom 43 achieved an objective response (93·5%, 95% CI 82·1–98·6) including two complete responses (4·3%, 0·5–14·8) and 41 partial responses (89·1%, 76·4–96·4). Treatment-related adverse events of grade 3 were recorded in 12 (26%) of 46 patients, including two patients each experiencing decreased neutrophil count and increased blood creatine phosphokinase. Serious adverse events occurred in five patients (11%). No grade 4 adverse events or deaths were reported. The study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment. Interpretation CH5424802 is well tolerated and highly active in patients with advanced ALK -rearranged NSCLC. Funding Chugai Pharmaceutical Co, Ltd.
- Published
- 2013
11. OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts)
- Author
-
Haruyasu Murakami, Kengo Takeuchi, Yuichiro Ohe, Makoto Nishio, Akira Inoue, K. Kiura, S. Inamura, Tomohide Tamura, Hiroshi Kuriki, Naoyuki Nogami, Kazuhiko Nakagawa, Tadashi Shimada, Masao Harada, Makoto Maemondo, Toyoaki Hida, Takashi Seto, and Hiroshige Yoshioka
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Alectinib ,business.industry ,medicine.drug_class ,ALK inhibitor ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Phase i ii ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Medicine ,business - Published
- 2017
12. Analyses of Terminal Groups for Poly(propylene oxide) Polyols
- Author
-
Tadashi Shimada and Shigeaki Yonemori
- Subjects
Poly(propylene oxide) ,Polymers and Plastics ,Terminal (electronics) ,Chemistry ,Materials Science (miscellaneous) ,Polymer chemistry ,Chemical Engineering (miscellaneous) ,Organic chemistry ,General Environmental Science - Abstract
イソシアナートと反応させてポリウレタンを生成するポリ (プロピレンオキシド) 系ポリオールの末端基の解析法として, 直接1Hおよび13C NMRを用いない方法を総合的に研究した. 末端基としては, ヒドロキシル基と少量の不飽和基の2種が存在しており, ヒドロキシル基の定量 (ヒドロキシル基価) には, ピリジン溶液でのフタル酸エステル化法 (JIS法) に替わる近赤外法を開発した. また定性では, トリフルオロ酢酸付加物の19F NMRによる解析法を示した. 水酸末端基数の違いによる高速液体クロマトグラフィー (HPLC) による分離法を確立した. 不飽和基の定量法として酢酸第二水銀法に替わる一塩化ヨウ素付加による方法を, また不飽和基のアリル基・cis-プロペニル基の識別法としてラマン法を示した.
- Published
- 2003
13. Aluminum titanate-tetragonal zirconia composite with low thermal expansion and high strength simultaneously
- Author
-
Yukio Nurishi, Masatoshi Mizuno, Minoru Hashiba, Daisuke Mizuno, Teruaki Ono, Tadashi Shimada, Osamu Sakurada, and Kouji Katou
- Subjects
Materials science ,Metallurgy ,Alloy ,Sintering ,chemistry.chemical_element ,General Chemistry ,engineering.material ,Condensed Matter Physics ,Microstructure ,Titanate ,Thermal expansion ,chemistry ,Aluminium ,engineering ,General Materials Science ,Cubic zirconia ,Composite material ,Yttria-stabilized zirconia - Abstract
Aluminium titanate was strengthened by alloying with 3 mol% yttria stabilized zirconia to attain a small expansion coefficient of 2 × 10 −6 and a high strength of 100 MPa, simultaneously. Long milling and optimization of the composition of the alloy to an equal weight of the component oxides and also of the firing temperature at 1400 °C were important for the purpose. In the optimal conditions, aluminum titanate grains of 3 μm was surrounded by zirconia matrix of ca. 0.3 μm grains containing zirconium titanate where would be a balance between the tension in the matrix and the expansion force of aluminum titanate grains. Formation of zirconium titanate was important for the strengthening to decrease the lowering of the strength brought about by the unstabilization of PSZ.
- Published
- 1997
14. A CASE OF ADENOID CYSTIC CARCINOMA OF THE BREAST
- Author
-
Kiyoshi Nakayasu, Shigeto Maeda, Satoshi Kurata, Yoshikazu Kaneda, Yutaka Kuroda, Toshiaki Kamei, Takashi Hujiwara, Hideyuki Sakai, Tadashi Shimada, and Hiroshi Hongou
- Subjects
Pathology ,medicine.medical_specialty ,medicine.diagnostic_test ,biology ,business.industry ,Adenoid cystic carcinoma ,medicine.disease ,Malignancy ,Metastasis ,medicine.anatomical_structure ,Carcinoembryonic antigen ,Biopsy ,medicine ,biology.protein ,business ,Duct (anatomy) ,Lymph node ,Hyaline - Abstract
A case of adenoid cystic carcinoma of the breast is reported. A 70-year-old woman was referred to our clinic with the chief complaint of right breast pain. The impression of the mass was chronic mastopathy, but a possible malignancy was suspected ultrasonographycally. Excisional biopsy and pathological examination revealed an adenoid cystic carcinoma. Patey operation was performed, no metastasis to axillary lymph node being found. Histologically, the tumor was characterized by “cysts” with a cribriform pattern. Histochemically, hyaline material inside “cysts” were alcian blue-positive and PAS-negative or weakly positive, and contents of the duct structures gave a positive reaction with PAS but negative with alcian blue. Immunohistochemically, CEA (carcinoembryonic antigen) and secretory component were disclosed in the duct structures, but none in the “cysts”.
- Published
- 1991
15. A CASE OF SYNCHRONUS EARLY DOUBLE CARCINOMA OF THE STOMACH AND PAPILLA OF VATER
- Author
-
Tadashi Shimada, Hiroshi Hongo, Toshiaki Kamei, Shigeto Maeda, Satoru Kurata, Yutaka Kuroda, Kiyoshi Nakayasu, and Hidenori Sakai
- Subjects
medicine.medical_specialty ,business.industry ,Stomach ,medicine.medical_treatment ,medicine.disease ,Pancreaticoduodenectomy ,digestive system ,Gastroenterology ,Epigastric pain ,digestive system diseases ,Metastasis ,Major duodenal papilla ,medicine.anatomical_structure ,Internal medicine ,medicine ,Carcinoma ,Acute pancreatitis ,Adenocarcinoma ,business - Abstract
A 52-year-old man visited our hospital, complaining of epigastric pain. ERCP, which was performed under a suspicion of acute pancreatitis due to his alcoholophilia, and gastrcendoscopy led to a preoperative diagnosis of synchronous early double carcinoma of the stomach and papilla of Vater. Pancreaticoduodenectomy was carried out. Carcinoma of the papilla of Vater was measured 1.1×1.0cm in size and histopathologically diagnosed as a moderatelly differentiated tubullar adenocarcinoma which slightly invaded the Oddi's muscle. Gastric cancer located on the gastric angle was 0.3×0.2cm in size. It was a well differentiated tubullar adenocarcinoma of type IIc limited to the mucosal layer. Any regional lymphnode metastasis was not found.
- Published
- 1990
16. A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP
- Author
-
Tomohide Tamura, Naoyuki Nogami, Kazuhiko Nakagawa, Hiroshi Kuriki, Tomohiro Tanaka, Makoto Maemondo, Tadashi Shimada, Haruyasu Murakami, Hiroshige Yoshioka, Toyoaki Hida, Yuichiro Ohe, Takashi Seto, Makoto Nishio, Katsuyuki Kiura, Akira Inoue, Masao Harada, and Kengo Takeuchi
- Subjects
Alectinib ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,medicine.disease ,Surgery ,ALK inhibitor ,chemistry.chemical_compound ,Phase i ii ,Oncology ,chemistry ,Tolerability ,hemic and lymphatic diseases ,medicine ,Cancer research ,Progression-free survival ,Non small cell ,Penetrant (biochemical) ,Lung cancer ,business - Abstract
8061 Background: Alectinib, a CNS-penetrant, selective ALK inhibitor with a novel scaffold, was granted approval in Japan 2014, since it showed good efficacy and tolerability in ALK+ NSCLC pts with...
- Published
- 2015
17. Anti-Tumor Activity of Alectinib in Crizotinib Pre-Treated Alk-Rearranged Nsclc in Jp28927 Study
- Author
-
Kentaro Takeda, Tomohiro Tanaka, M. Nishio, Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida, Miyako Satouchi, Kazuhiko Nakagawa, Takashi Seto, Masahiro Tatsuno, Katsuyuki Hotta, Tomohide Tamura, and Tadashi Shimada
- Subjects
Oncology ,Alectinib ,medicine.medical_specialty ,FOOD EFFECT ,Crizotinib ,business.industry ,medicine.drug_class ,Tumor shrinkage ,Hematology ,Disease control ,First generation ,ALK inhibitor ,Safety profile ,Internal medicine ,medicine ,business ,Intensive care medicine ,medicine.drug - Abstract
Aim: Alectinib is a CNS-penentrant, highly selective ALK inhibitor with a novel scaffold. JP28927 is a clinical pharmacological study to evaluate the bioequivalence of alectinib 300 mg b.i.d. with 20 and 40 mg capsules (caps) vs. 150 mg caps and food effect with 150mg caps in ALK-rearranged NSCLC patients (pts), regardless of history of previous ALK inhibitor treatment. Results for bioequivalence, food effect, efficacy and safety were reported at ASCO2014. ALK-rearranged NSCLC pts had to discontinue treatment from crizotinib, a first generation ALK inhibitor, because of drug resistance or intolerance. Methods: 35 ALK-rearranged NSCLC pts were enrolled into JP28927 study. Pts continued alectinib 300 mg b.i.d. with 150 mg caps until the investigator determined lack of clinical benefit. This report describes the updated efficacy and safety data for alectinib in 28 crizotinib pre-treated NSCLC pts included in JP28927. Results: As of Jan 11, 2014, median follow-up duration was 141 days (range: 35-166) and 21 pts continued treatment with alectinib without progressive disease (PD). Among 24 pts with target lesions, tumor shrinkage of more than 30 % was observed in 18 pts. Confirmed response rate was 58.3% (95%CI: 36.6-77.9) and disease control rate was 83.3 % (95%CI: 62.6-95.3) by investigator assessment. 19 of 28 pts had brain metastases at baseline, and 6 pts had no prior brain irradiation. 13 pts with brain metastases, including 4 pts without prior brain irradiation, were still on study treatment without PD. The safety profile was favorable, and continued the same trend previously reported. No pts discontinued study treatment for a safety reason. Gastrointestinal and visual disorders, characteristic of crizotinib treatment, were mild and not so frequent with alectinib. Conclusions: Alectinib showed promising response, including in brain metastases, and good tolerability in crizotinib pre-treated pts. These findings suggest that alectinib is a novel therapeutic option for crizotinib pre-treated ALK-rearranged NSCLC. Disclosure: T. Seto: Other substantive relationships: Honoraria (Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma K.K.), Research funding(Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma K.K., Astellas Pharma Inc.); T. Hida: Corporate sponsored research: Chugai, Pfizer, Novartis; K. Nakagawa: Advisory board: Abbott Japan Co., Ltd. Astellas Pharma Inc. Chugai Pharmaceutical Co.,Ltd. Pfizer Japan Inc.Novartis Pharma K.K. Corporate sponsored research:Chugai Pharmaceutical Co.,Ltd.Pfizer Japan Inc.Novartis Pharma K.K.; M. Satouchi: Corporate sponsored research:Chugai, Pfizer, Novartis Other substantive relationships:Honoraria; Chugai, Pfizer, Novartis; M. Nishio: Corporate sponsored research:Chugai, Novartis, Pfizer Other substantive relationships:Honoraria; Chugai, Novartis, Pfizer; K. Hotta: Corporate sponsored research: Chugai Other substantive relationships:Honoraria; Chugai, Pfizer; H. Murakami: Corporate sponsored research:Chugai, Novartis, Astellas; Y. Ohe: Corporate sponsored research: Chugai, Pfizer Other substantive relationships: Honoraria; Chugai, Pfizer; K. Takeda: Other substantive relationships: Chugai, Pfizer, Novartis; M. Tatsuno: Chugai employee; T. Shimada: Chugai employee; T. Tanaka: Chugai employee; T. Tamura: Corporate sponsored research: Chugai, Astellas, AbbVie (Abbott) Other substantive relationships: Honoraria; Chugai, Astellas, Novartis.
- Published
- 2014
18. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP
- Author
-
Akira Inoue, Nobuyuki Yamamoto, Makoto Maemondo, Tomohiro Tanaka, Yuichiro Ohe, Katsuyuki Kiura, Hiroshige Yoshioka, Toyoaki Hida, Makoto Nishio, Kengo Takeuchi, Takashi Seto, Tadashi Shimada, Kazuhiko Nakagawa, Masao Harada, Tomohide Tamura, and Naoyuki Nogami
- Subjects
Cancer Research ,business.industry ,medicine.drug_class ,ALK-Positive ,non-small cell lung cancer (NSCLC) ,Chromosomal rearrangement ,medicine.disease ,Highly selective ,ALK inhibitor ,Fusion gene ,Oncology ,medicine ,Cancer research ,Anaplastic lymphoma kinase ,business ,Tyrosine kinase - Abstract
8033 Background: Anaplastic lymphoma kinase (ALK) is a constitutively activated tyrosine kinase in a subset of NSCLC with ALK fusion gene derived from chromosomal rearrangement. Previously, CH5424802, a highly selective, second-generation ALK inhibitor, has demonstrated clinically meaningful antitumor activity and a favorable toxicity profile (ESMO 2012). Here we report the updated results of this study. Methods: Patients (Pts) with ALK-positive NSCLC and no prior ALK inhibitor therapy were treated with CH5424802 at 300 mg bid until progressive disease or intolerable toxicity to investigate the efficacy and safety. Results: As of the cut-off date of Dec. 14, 2012, 58 pts have been treated with CH5424802: median age 49.5 years, M/F 25/33, ECOG PS 0/1 26/32, never-smoker 60.3%, ≥2 prior chemotherapy regimens 62%. Among the 46 pts in phase II part of this study, the overall response rate was 93.5% (95% CI: 82.1%, 98.6%) with 2 CRs and 41 PRs. Tumor shrinkage by 30% (PR) was achieved quickly with 65% occurring within 3 weeks of treatment and 87% within 6 weeks. With a median follow-up period of 12.6 months, 47/58 pts (40/46 pts in phase II part) were still on study treatment, and the median treatment duration has passed 10.3 months. The major treatment-related AEs were dysgeusia (21/58, 36%), rash, AST increased, blood bilirubin increased (19/58, 33% each), constipation and blood creatinine increased (17/58, 29% each), mostly grade 1-2. The major treatment-related grade 3 AEs were neutrophil count decreased (4/58, 7%). No grade 4 or fatal AEs were observed. Treatment-related visual disorders, vomiting and nausea were rare and mild. Conclusions: In patients with ALK-positive NSCLC but naïve to any ALK inhibitor therapy, treatment with CH5424802 demonstrated generally mild toxicity and lead to high response rate of 93.5% and durable treatment beyond 10 months, expecting that treatment duration can be longer than that of crizotinib. CH5424802 is therefore a promising new ALK inhibitor for NSCLC. Clinical trial information: JapicCTI-101264.
- Published
- 2013
19. A Phase II Study of Pemetrexed in Chemotherapy-Naive Elderly Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer: Hanshin Oncology Group 003
- Author
-
Tadashi Shimada, Yoshihiro Hattori, Takashi Nishimura, Yoshikazu Kotani, Masahiro Iwasaku, S. Negoro, Fumio Imamura, Miyako Satouchi, Masahide Mori, Yoshinobu Namba, M. Edagawa, Shiro Fujita, N. Katagami, Hiroshige Yoshioka, and Satoshi Morita
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Phases of clinical research ,Hematology ,Neutropenia ,Vinorelbine ,medicine.disease ,Gemcitabine ,Pemetrexed ,Internal medicine ,medicine ,Progression-free survival ,business ,Lung cancer ,medicine.drug - Abstract
Background Single-agent chemotherapy (i.e. doxetaxel, gemcitabine or vinorelbine) is one of the standard treatments for elderly patients with advanced NSCLC. Pemetrexed has clinically equivalent efficacy, but with less toxicity compared with doxetaxel in the second-line setting of patients with advanced NSCLC. We conducted a phase II trial to evaluate the efficacy and safety of frontline pemetrexed in elderly patients with advanced non-squamous (non-Sq) NSCLC. Methods In this multicenter phase II trial, we recruited elderly patients with non-Sq NSCLC. Eligibility criteria were as follows: chemonaive; locally advanced or metastatic non-Sq NSCLC; age 75 or older; ECOG performance status 0-1; adequate organ function. Patients received pemetrexed (500 mg/m2) intravenously on day 1 every 3 weeks until disease progression had been confirmed. The primary end point was response rate (RR). The secondary end points included progression free survival (PFS), overall survival (OS), disease control rate (DCR) and safety. The planned sample size was 45 patients. Results Between August 2009 and July 2011, 47 patients were enrolled. Median age was 79 years (range: 75–91), 57% (20 of 47) were male, 36% (17 of 47) had never smoked, 85% (40 of 47) had adenocarcinoma, 72% (34 of 47) had stage IV and 41% (16 of 39) had EGFR tyrosine kinase activating mutation. Median number of cycles was 4 (1 to 15). RR was 13.3% (95% CI: 5.1, 26.8), DCR was 66.7% (95% CI: 51.0, 80.0), PFS was 4.9 months (95% CI: 3.0, 6.2 months), median OS was not reached. The most frequent treatment-related AEs were anemia, fatigue, hypocalcemia, mostly grade 1/2. Treatment-related grade 3/4 AEs were reported in 17.8% of patients (mostly neutropenia and fatigue). No treatment-related death occurred. Conclusions The efficacy and limited side-effects of pemetrexed are promising in elderly patients with non-Sq NSCLC.
- Published
- 2012
20. Prefectural Research Institute in Regional Textile Industries
- Author
-
Tadashi Shimada
- Subjects
Engineering ,business.industry ,General Medicine ,business ,Textile (markup language) ,Process engineering ,Manufacturing engineering - Published
- 2006
21. Synaptic mechanisms of urethane-induced electrocortical slow waves in the rat
- Author
-
Keiko Arai, Yuji Mukasa, Tomokazu Oshima, Tadashi Shimada, and Sanae Tomizawa
- Subjects
Pharmacology - Published
- 1995
22. Electrocortical and neuronal activities of rat motor cortex in neuroleptanalgesia with droperidol and pentazocine
- Author
-
Yuji Mukasa, Tadashi Shimada, Keiko Arai, Sanae Tomizawa, and Tomokazu Oshima
- Subjects
Pharmacology ,Neuroleptanalgesia ,medicine.anatomical_structure ,Pentazocine ,business.industry ,Anesthesia ,medicine ,business ,Droperidol ,medicine.drug ,Motor cortex - Published
- 1995
23. GABAergic mechanisms in the rat motor cortex during neuroleptanalgesia with diazepam and pentazocine
- Author
-
Tadashi Shimada, Keiko Arai, Yuji Mukasa, Tomokazu Oshima, and Sanae Tomizawa
- Subjects
Pharmacology ,Neuroleptanalgesia ,Pentazocine ,medicine.anatomical_structure ,business.industry ,GABAergic ,Medicine ,business ,Neuroscience ,Diazepam ,medicine.drug ,Motor cortex - Published
- 1995
24. Effects of atropine on the long-term potentiation of intracortical direct responses in rat motor cortex
- Author
-
Keiko Arai, Tomokazu Oshima, Sanae Tomizawa, Yuji Mukasa, and Tadashi Shimada
- Subjects
Pharmacology ,Atropine ,medicine.anatomical_structure ,business.industry ,Medicine ,Long-term potentiation ,business ,Neuroscience ,medicine.drug ,Motor cortex - Published
- 1995
25. Electrocortical and neuronal activities of rat motor cortex in anesthesia by diazepam with analgesics
- Author
-
Mariko Noguchi, Tomokazu Oshima, Keiko Arai, Koji Fukano, Sanae Tomizawa, Yuji Mukasa, and Tadashi Shimada
- Subjects
Pharmacology ,medicine.anatomical_structure ,business.industry ,Anesthesia ,medicine ,business ,Diazepam ,medicine.drug ,Motor cortex - Published
- 1994
26. Blocking effects of brainstem stimulation on urethane-induced electro-cortical slow waves in the rat
- Author
-
Keiko Arai, Tomokazu Oshima, Tadashi Shimada, Maki Okamura, Naomi Inagaki, Yuji Mukasa, and Kumiko Arai
- Subjects
Pharmacology ,Chemistry ,Blocking (radio) ,Biophysics ,Stimulation ,Brainstem - Published
- 1994
27. Desensitization of Ca2+-dependent intracellular alkalization by muscarinic stimulation with carbachol in smooth muscle
- Author
-
Tadashi Shimada, Tomokazu Oshima, Eiji Yomota, Masaatsu K. Uchida, and Shigeru Hishinuma
- Subjects
Pharmacology ,Carbachol ,Smooth muscle ,Chemistry ,medicine.medical_treatment ,Muscarinic acetylcholine receptor ,medicine ,Stimulation ,Intracellular ,Desensitization (medicine) ,medicine.drug - Published
- 1994
28. A Study on Chlorhexidine with Reference to its Adverse Effect and Development of Resistant Strains
- Author
-
Tadashi Shimada, Shigeru Yamada, Tetsu Koyama, Seiji Ema, Masatoshi Arita, and Keiji Okada
- Subjects
business.industry ,Chlorhexidine ,Medicine ,General Medicine ,business ,Adverse effect ,Microbiology ,medicine.drug - Published
- 1974
29. Pancreaticoduodenectomy for severe trauma to the head of the pancreas. Report of three cases
- Author
-
Tadashi Shimada, Satoru Kurata, Hiroshi Hiongoh, Takashi Nakamura, Hiroyoshi Abiru, Kaoru Ohfuji, Kiyoshi Nakayasu, Naotsugu Kondoh, and Takuo Shinozaki
- Subjects
medicine.medical_specialty ,business.industry ,General surgery ,medicine.medical_treatment ,Gastroenterology ,Pancreaticoduodenectomy ,Surgery ,medicine.anatomical_structure ,Severe trauma ,medicine ,Head (vessel) ,Pancreas ,business - Published
- 1987
30. Adverse Effect of Chlorhexidine and the Development of Resistant Strains, of Bacteria
- Author
-
Tetsu Koyama, Seiji Ema, Masatoshi Arita, Keiji Okada, Shigeru Yamada, and Tadashi Shimada
- Subjects
Dose ,Biguanides ,Dental Plaque ,Mouthwashes ,Administration, Oral ,Dentistry ,law.invention ,Streptococcus mutans ,Mice ,Chlorhexidine digluconate ,law ,medicine ,Animals ,Humans ,Oral mucosa ,Child ,Adverse effect ,biology ,business.industry ,Chlorhexidine ,Streptococcus ,Drug Resistance, Microbial ,biology.organism_classification ,Rats ,stomatognathic diseases ,medicine.anatomical_structure ,Toothbrush ,business ,Bacteria ,medicine.drug - Abstract
The authors studied the possibility of adverse effects of chlorhexidine digluconate as applied to the oral area and the possible development of resistant Streptococcus mutans as a result of prolonged application.Different groups of experimental rats were respectively treated with 0.2% and 2.0% aquous solutions of chlorhexidine digluconate for 35 days. However, there were not observed any abnormal findings on the dental surfaces, gingivae and oral mucosa.In another series of tests with mice to which chlorhexidine digluconate was orally administerea in 5 different dosages of 12mg/Kg, 120mg/Kg, 180mg/Kg, 240mg/Kg, and 300mg/Kg, the 12mg/Kg group was found to show a normal healthy growth without abnormal findings.Five Streptococcus mutans strains were subjected to the dilution method in an effort to study the possibility of the development of resistant strains as a result of prolonged use of chlorhexidine digluconate. The result indicated that it would be difficult for resistant strains to develop.An experiment with primary school pupils, in which 3rd grade pupils were either treated with 2.0% solution or rinse of chlorhexidine digluconate in conjunction with instruction in the proper use of the toothbrush for a year, showed no abnormalcy on the dental surfaces, gingivae and oral mucosa. An application of chlorhexidine digluconate on a weekly basis proved successful in inhibiting the formation of dental plaques, and findings of this part of our studies will be given in a later report.
- Published
- 1974
31. ABDOMINAL AORTIC ANEURYSM WITH COINCIDENTAL MALIGNANCY
- Author
-
Takuo Shinozaki, Tadashi Shimada, Kaoru Ohfuji, Hiroyoshi Abiru, Takashi Nakamura, Hiroshi Hongo, Naotugu Kondo, Satoru Kurata, and Kiyoshi Nakayasu
- Subjects
medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,Malignancy ,Abdominal aortic aneurysm ,Surgery ,Hemorrhagic complication ,Pulmonary cancer ,medicine ,Radiology ,Myocardial infarction ,Stage (cooking) ,Lung cancer ,business - Abstract
In 16 cases of abdominal aortic aneurysm (AAA) which we have treated surgically during the past two and half years, coincidental malignancy was encountered in four, i.e., three of gasric cancer and one of pulmonary cancer. The diagnosis of AAA and gastric or lung cancer was made simultaneously and preoperatively in cases 1, 2. AAA was diagnosed after 1.7 years and four years respectively, following the treatment of gastric cancer in cases 3 and 4. In case 1, gastric cancer with hemorrhagic complications was resected first, and aneurysmectomy was carried out on the 38th postoperative day. In case 2, a large AAA 6cm in size was wrapped first and a left upper lobectomy was done on the 19th postoperative day. In the other two patients, who were free of acertainable recurrence, aneurysmectomy was carried out in the early stage of gastric cancer in case 3, and wrapping was done in advanced gastric cancer in case.4. Case 2 died of myocardial infarction in third postoperative month. The other three patients are alive. In a patient with two life-threatening and separate diseases, surgical indications, method of the operation and priority of treatments should be carefully considered.
- Published
- 1986
32. Reciprocal effects of capsaicin and menthol on thermosensation through regulated activities of TRPV1 and TRPM8
- Author
-
Hiroshi Matsui, Tadashi Shimada, Fumitaka Fujita, Makoto Tominaga, Yoshiro Suzuki, Kunitoshi Uchida, and Masayuki Takaishi
- Subjects
0301 basic medicine ,TRPM8 ,Adult ,Male ,Physiology ,TRPV1 ,TRPM Cation Channels ,TRPV Cation Channels ,Stimulation ,Pharmacology ,medicine.disease_cause ,Cell Line ,03 medical and health sciences ,chemistry.chemical_compound ,Transient receptor potential channel ,Young Adult ,0302 clinical medicine ,In vivo ,medicine ,Humans ,Pain Measurement ,Original Paper ,Analgesics ,musculoskeletal, neural, and ocular physiology ,Cold Temperature ,Menthol ,030104 developmental biology ,HEK293 Cells ,chemistry ,nervous system ,Capsaicin ,Analgesic ,lipids (amino acids, peptides, and proteins) ,Irritation ,030217 neurology & neurosurgery - Abstract
Transient receptor potential vanilloid 1 (TRPV1) is activated by elevated temperature (>42 °C), and it has been reported that cold temperature decreases capsaicin-induced TRPV1 activity. In contrast, transient receptor potential melastatin 8 (TRPM8) is activated by low temperatures and menthol, and heat stimulation suppresses menthol-evoked TRPM8 currents. These findings suggest that the effects of specific agents on TRPV1 and TRPM8 channels are intricately interrelated. We examined the effects of menthol on human (h)TRPV1 and of capsaicin on hTRPM8. hTRPV1 currents activated by heat and capsaicin were inhibited by menthol, whereas hTRPM8 currents activated by cold and menthol were similarly inhibited by capsaicin. An in vivo sensory irritation test showed that menthol conferred an analgesic effect on the sensory irritation evoked by a capsaicin analogue. These results indicate that in our study the agonists of TRPV1 and TRPM8 interacted with both of these channels and suggest that the anti-nociceptive effects of menthol can be partially explained by this phenomenon. Electronic supplementary material The online version of this article (doi:10.1007/s12576-015-0427-y) contains supplementary material, which is available to authorized users.
- Full Text
- View/download PDF
33. [The correlation among the frequency of toothbrushing, degree of dental cleanliness and PMA index in secondary school pupils]
- Author
-
Tetsu Koyama, Shigeru Yamada, Jen-Chih Chuang, Tadashi Shimada, Kazuhiro Ichikawa, and Seiji Ema
- Subjects
Toothbrushing ,Risk level ,Index (economics) ,Adolescent ,business.industry ,Statistical difference ,Dentistry ,Oral Hygiene ,Degree (temperature) ,Correlation ,Medicine ,Humans ,Longitudinal Studies ,Periodontal Index ,business - Abstract
The present study was conducted for the purpose of elucidating the correlation of three items: i) the frequency of toothbrushing, ii) the degree of dental cleanliness, and iii) the PMA index for a three-year period till the graduation of the subjects from lower secondary school. The subjects were instructed to brush their teeth thoroughly in the inital examination of each year, and their oral conditions were examined for a total of 13 times, on an average of 3 to 5 times per year.When the correlative coefficient (r) was calculated based on the study, there was observed a weak minus correlation between the frequency of toothbrushing and the degree of dental cleanliness but there was no statistical difference between the frequency of toothbrushing and the PMA index, the statistical difference being about 1% risk level between the frequency of toothbrushing and the PMA index.When the 1975 data were analyzed concerning the above items, the correlation between the degree of dental cleanliness and the frequency of thoothbrushing and the PMA index was given the main attention. As a result, it was found that the correlation between the degree of dental cleanliness and the PMA index was +0.320-+0.578, with a fair degree of positive correlation.The correlation, on the other hand, between the degree of dental cleanliness and frequency of toothbrushing was slight, with a value of -0.084- -0.198.As stated above, a total of 314 children were subjected to the study for a consecutive period of three years. But some of the subjects were for a period of two years.
- Published
- 1977
34. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
- Author
-
Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, and Nishio M
- Subjects
- Adult, Aged, Anaplastic Lymphoma Kinase, Antineoplastic Agents adverse effects, Carbazoles adverse effects, Carcinoma, Non-Small-Cell Lung chemistry, Carcinoma, Non-Small-Cell Lung secondary, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Hyperbilirubinemia chemically induced, Lung Neoplasms chemistry, Lung Neoplasms pathology, Male, Middle Aged, Piperidines adverse effects, Receptor Protein-Tyrosine Kinases analysis, Retreatment, Survival Rate, Symptom Assessment, Time Factors, Antineoplastic Agents therapeutic use, Carbazoles therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Piperidines therapeutic use, Receptor Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
Purpose Alectinib is an anaplastic lymphoma kinase (ALK) -specific kinase inhibitor that seems to be effective against non-small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overall response rate. To assess progression-free survival (PFS) and overall survival (OS), patients from the phase II part of AF-001JP were followed up for approximately 3 years. Patients and Methods Oral alectinib 300 mg was administered twice per day to patients with ALK inhibitor-naïve, ALK-positive NSCLC who had progressed after one or more regimens of previous chemotherapy. In this long-term follow-up, efficacy (PFS, OS), correlation between tumor shrinkage and PFS, safety of alectinib, and relief of cancer symptoms were evaluated. Results At the updated data cutoff (September 10, 2015; first patient in August 30, 2011, last patient in April 18, 2012), 25 of 46 phase II patients were still receiving alectinib. Disease progression was confirmed in 18 patients (39%); median PFS was not reached (3-year PFS rate, 62%; 95% CI, 45 to 75). Fourteen patients had brain metastases at baseline; of these, 6 remained in the study without CNS and systemic progression. Tumor shrinkage and PFS showed no correlation. The 3-year OS rate was 78% (13 events). The most common treatment-related adverse event (all grades) was increased blood bilirubin (36.2%). Most cancer symptoms were relieved early, and medication for symptoms was dramatically decreased during alectinib therapy. Conclusion Alectinib was effective in this 3-year follow-up with a favorable safety profile over a long administration period in ALK-positive NSCLC without previous ALK inhibitor treatment.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.